Capital Region Secures #3 National Ranking Among U.S. Biopharma Clusters
Montgomery County, Maryland is undisputably the epicenter for Life Sciences in the Capital Region, which has solidified its position as a national leading area for the life sciences industry, earning the #3 ranking in Genetic Engineering & Biotechnology News’ 2025 list of the Top 10 U.S. Biopharma Clusters. This recognition underscores the county’s dynamic biopharma industry, powered by some of the largest and innovative companies in the world, including AstraZeneca, Novavax, and United Therapeutics.
It is in Maryland’s largest, wealthiest, and most diverse county that more than 350 life sciences companies spanning biopharmaceuticals, gene and cell therapy, vaccines, diagnostics, medical equipment, and advanced manufacturing call home. That is no coincidence—from local and state biotech incentives to a robust ecosystem of partners, close proximity to federal agencies, including the National Institutes of Health (NIH), the National Institute of Standards and Technology (NIST), and the U.S. Food and Drug Administration (FDA), to a deep talent pool, there are significant advantages here. The county has the 2nd highest concentration of PHDs, and a life sciences labor force of more than 40,0000 workers.
Recently, global biopharmaceutical AstraZeneca opened a $300 Million cell therapy manufacturing facility in Rockville, adding to its established U.S. headquarters in Gaithersburg. The project, which was supported by $100,000 in county financial incentives, underscores Montgomery County’s ongoing commitment to fostering industry growth. As the county continues to thrive in Life Sciences, it is poised to remain a powerhouse for years to come.